NCT02775981已完成1 期
A Phase-1 Study Comparing the Pharmacokinetics of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cax)
研究概览
简要总结
The primary objective of this study is to evaluate the potential effect of hepatic impairment on the systemic pharmacokinetics of RX0041-002 following single dose intranasal administration. The secondary objective is to evaluate the safety and tolerability of intranasal RX0041-002 in subjects with normal hepatic function and hepatic impairment.
详细描述
This is a Phase 1, single dose, open-label study comparing the plasma pharmacokinetics and safety of RX0041-002 between subjects with hepatic impairment and age/gender/BMI-matched subjects with normal hepatic function.
DOSAGE
All subjects will receive a single treatment consisting of four (4) ml of a 4% solution of RX0041-002 (corresponding to 160 mg cocaine HCl) applied for 20 minutes to both nostrils using cotton pledgets. RX0041-002 Topical Solution (4%) will be provided by the Sponsor, supplied in 4 mL bottles. RX0041-002 Topical Solution contains citric acid, D&C Yellow No. 10, FD&C Green No. 3, sodium benzoate, and water.
DURATION OF STUDY
Total duration of study participation for each subject will be approximately 23 days not counting the variable 30 days for adverse event follow-up and resolution, if required. During that time, subjects will be screened for a maximum of 21 days and then confined to the study unit for approximately 45 hours for Day -1 evaluations, dosing (Day 1), blood sampling and safety assessments (Day 1-2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female.
- •Greater than or equal to 18 years of age and able to understand and comply with protocol requirements, provide written informed consent and HIPAA authorization; ± 10 years for individual age-matched controls.
- •Females (if of child-bearing potential and sexually active) and males (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method from the first dose and for 8 days following administration of study drug. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm, intrauterine device (IUD), condom, surgical sterilization, and progestin implant or injection. Prohibited methods include: the rhythm method or withdrawal.
- •BMI ≥ 18 ≤ 32 ; ± 20% for BMI-matched controls
- •Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance.
- •In general, good health aside from hepatic disease (for the hepatically impaired group only) and associated conditions as ascertained by physical examination (PE) including measurement of supine and standing vital signs, medical history, clinical laboratory evaluation, and 12-lead electrocardiogram (ECG).
- •Hepatic Subjects
- •Hepatic-impaired subjects will be Class B or C according to Child-Pugh classification. The hepatic impairment will have been identified by a typical medical history, physical examination, coagulation tests and abnormal liver function tests (including bilirubin and albumin) at screening.
- •Healthy Volunteers
- •Volunteers will be healthy and age, BMI and gender-matched controls for the hepatic subjects.
排除标准
- •A subject will be excluded from the study if he or she meets the following criteria:
- •Less than 18 years of age.
- •Has a known allergy to any ester based anesthetics including cocaine HCl, procaine, tetracaine, chloroprocaine, dibucaine, or benzocaine amide based anesthetic allergies are NOT exclusionary. Amide based anesthetics are : lidocaine, mepivicaine, bupivicaine, levobupivicaine, ropivicaine, etidocaine, prilocaine, and articaine.
- •Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study.
- •The use of amphetamines, methylphenidate or other stimulant prescription and nonprescription products such as pseudoephedrine, bronchial inhalers containing sympathomimetics (epinephrine or other beta-receptor agonist) or herbal products in the 7 days prior to screening or has a need to use these drugs during the course of the study.
- •Use of any Seratonin uptake inhibitor/Serotonin-norepinephrine reuptake inhibitors, antidepressants or tricyclic antidepressant up to7 days or 5 half-lives (whichever is longer) prior to screening or has a need to use these drugs during the screening period and throughout the time period of the trial.
- •Use of Monoamine Oxidase Inhibitor drugs up to 14 days prior to screening or has a need to use these drugs during the screening period and throughout the time period of the trial.
- •GI abnormalities
- •History of hepatitis (for healthy control subjects only)
- •Elevated aspartate aminotransferase/alanine aminotransferase /bilirubin (for healthy control subjects only),
- •Excessive use of alcohol/tobacco/caffeine.
- •Has previously received study drug.
- •Has a history of abuse of controlled substances, nasal or otherwise, or has damage to the nasal space, that in the opinion of the investigator might interfere with the ability to absorb RX0041-
- •Has severely traumatized mucosa or sepsis in the nasal cavity.
- •Has participated in an investigational study or received an investigational drug within 30 days preceding the randomization.
- •Is a pregnant or nursing mother.
- •Has a positive pregnancy test at Screening or Day -
- •Has a history of seizure, with the exception of febrile seizures.
- •Has symptomatic cardiovascular disease.
- •Has a history of or currently suffers from hyperthyroidism.
- •Has a known personal or family history of hereditary pseudocholinesterase deficiency. Study participants will be screened by asking about personal or family history of anesthetic reaction, anesthetic death, and previous diagnosis of psuedocholinesterase deficiency in a relative or personally. Subjects identified with pseudocholinesterase deficiency are at risk for delayed recovery with certain anesthetics (e.g. succinylcholine and ester-based anesthetics).
- •Has a known personal or family history of pheochromocytoma. Study participants will be specifically asked if they have been treated for a pheochromocytoma previously or if they have a family member who has been diagnosed with pheochromocytoma (since 10% of these are familial).
- •Has a known personal or family history of adrenal tumor.
- •Clinically significant ECG abnormalities, based upon the impression of the investigator.
- •Has a positive urine test result for drugs of abuse (amphetamines, barbiturates, cocaine metabolites, opiates and oxycodone) or cannabinoids at Screening or on Day 1; exception for hepatic subjects who may medically require one of the drugs for treatment (e.g., periodic opiates) and may, at the discretion of the investigator, be positive at screening, but must be negative at Day -
- •Blood chemistry values judged clinically significant by the investigator. aa.Donation of blood (one pint or greater) within four weeks prior to administration of study medication.
- •bb. Not suitable for entry into the study in the opinion of the investigator.
研究组 & 干预措施
Active
Experimental
RX0041-002
干预措施: RX0041-002 (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cax)
时间窗: 32 Hours
Area under the plasma concentration versus time curve (AUC)
时间窗: 32 Hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Hepatic Impairment Study For Crizotinib In Advanced Cancer PatientsAdvanced CancerNCT01576406Pfizer88
已完成
1 期
Evaluation Of Hepatic Impairment On AG-013736 PharmacokineticsHepatic InsufficiencyNCT00692341Pfizer24
已完成
1 期
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of AgeCoughNCT06222892Bellus Health Inc. - a GSK company32
已完成
1 期
Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic FunctionHepatic ImpairmentNCT02452801Alkermes, Inc.40
已完成
1 期
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantNon-alcoholic Steatohepatitis (NASH)NCT05553470Corcept Therapeutics19